Sp1 binding sites have been identi®ed in enhancer/ promoter regions of several growth and cell cycle regulated genes, and it has been shown that Sp1 is increasingly phosphorylated in G1 phase of the cell cycle. Interactions of Sp1 with proteins involved in control of cell cycle and tumor formation have been reported. Here we show that expression of Sp1 protein predominates in the G1 phase of the cell cycle in epithelial cells. This is achieved by proteasome-dependent degradation. Inhibition of endogeneous Sp1 activity by a dominant-negative Sp1 mutant was associated with a cell cycle arrest in G1 phase, a strongly reduced expression of cyclin D1, the EGF-receptor and increased levels of p27Kip1. We have thus identi®ed Sp1 as an important regulator of the cell cycle in G1 phase.
Introduction
Sp1 is one of the very ®rst cellular transcription factors to be identi®ed and cloned (Kadonaga et al., 1987) . Structure-function analysis of Sp1 has revealed the presence of three separate regions involved in its transcription regulatory functions: (1) multiple transactivation domains; (2) domain involved in multimerization and cooperative transactivation; and (3) a carboxyl-terminal DNA-binding domain consisting of three zinc ®nger motifs Pascal and Tjian, 1991) . A variety of biological functions has been assigned to Sp1, but its role for the cell cycle is incompletely understood. Involvement of Sp1 in mediating responses to growth regulating stimuli such as TGF-beta, EGF and cAMP has been reported (Inagaki et al., 1994; Merchant et al., 1999; Venepally and Waterman, 1995) . However, inactivation of the mouse Sp1 gene by targeted disruption revealed that the cell cycle of embryonic stem cells was not aected (Marin et al., 1997) . In contrast several other reports suggested a role for Sp1 in the cell cycle. It was shown that Sp1 is phosphorylated in response to growth factors (Black et al., 1999) and it interacts with certain cell cycle regulatory proteins such as cyclin D1 and the retinoblastoma protein (Adnane et al., 1999 , Kim et al., 1992 Opitz and Rustgi, 2000; Chang et al., 2001) . Furthermore, Sp1 interacts with the retinoblastomarelated protein p107 (Datta et al., 1995) , the transcription factor E2F (Karlseder et al., 1996) , p53 (Gualberto and Baldwin, 1995) and mdm2 (JohnsonPais et al., 2001 ). Here we have investigated the role of Sp1 for the cell cycle in epithelial cells. We observed that Sp1 protein expression predominates in G1 phase of the cell cycle, most likely due to a cell cycle dependent degradation by the proteasome-dependent system. Inactivation of Sp1 by a dominant-negative mutant blocked cell cycle progression in G1 phase. A reporter gene assay showed that the dominant-negative Sp1 mutant strongly reduced endogeneous cellular Sp1 activity and inhibited expression of cyclin D1 and EGFR, while p27Kip1 expression was upregulated. Thus we have identi®ed Sp1 as a transcription factor involved in controlling the cell cycle in G1 phase.
Results

Cell cycle dependent Sp1 expression in epithelial cells
To investigate whether Sp1 protein expression is cell cycle regulated, we analysed Sp1 in synchronized HBL-100 and HeLa cells. HBL-100 cells were synchronized as described (Grinstein et al., 1996) . Sp1 protein expression was analysed by immunoblotting of nuclear extracts ( Figure 1a) . In S phase and G2 phase a low amount of Sp1 protein was detected (Figure 1a , top, lanes 2 and 3). However, in G1 phase Sp1 was strongly expressed (Figure 1a , top, lane 1). To con®rm cell synchronization eciencies, expression of cyclin A was examined (Figure 1a , bottom). Protein amounts were controlled by analysis of Oct1 protein which is equally expressed in all phases of the cell cycle (La Bella and Heintz, 1991) (Figure 1a , middle). To investigate whether the actual DNA binding activity of Sp1 is cell cycle regulated, we used an electrophoretic mobility A B C Figure 1 Cell cycle regulation of Sp1 expression. (a) HBL-100 cells were synchronized according to cell cycle stage, and nuclear extracts were analysed for Sp1 protein expression by Western blotting using antibody directed against the Sp1 protein (top). Lane 1, G1 phase; lane 2, S phase; lane 3, G2 phase. Sp1 is indicated by an arrow. Cell synchronization (see Materials and methods) was con®rmed by re-blotting the membrane with an antibody to cyclin A (bottom). Western blot with an antibody to the transcription factor Oct1 served as internal control (middle). (b) Electrophoretic mobility shift assay with the same extracts used as in (a). To detect Sp1 DNA-binding activity a labeled Sp1 recognition site was used. Conditions for EMSA are described in Materials and methods. Lane 1, G1 phase; lane 2, S phase; lane 3, G2 phase. The retarded Sp1 complex is indicated by an arrow. The presence of Sp1 in the retarded complex was controlled by an immunoshift (lanes 4 ± 8). The samples in lanes 5 and 6 contained 1 and 3 ml of an antibody speci®c for Sp1. The samples in lanes 7 and 8 contained 1 and 3 ml of an antibody speci®c for DP1. (c) HBL-100 cells were logarithmically grown (cycling) or were synchronized according to cell cycle stage, G1, S, G2, as shown in Figure 1a and as described in Matherials and methods. Sp1 protein expression was detected using antibody to Sp1 by means of immunoperoxidase staining kit G1 phase control by Sp1 E Grinstein et al shift assay (Figure 1b) . The ®gure shows that the DNA binding activity of Sp1¯uctuates during the cell cycle much like the nuclear Sp1 protein (lanes 1 ± 3). The retarded Sp1 DNA/protein complex is indicated by an arrow. The presence of Sp1 in this complex was controlled by an immunoshift, using an antibody directed against Sp1 (lanes 5 and 6). As additional control an antibody speci®c for DP1 was used in the immunoshift experiment (lanes 7 and 8). Next, Sp1 expression in nuclear extracts of synchronized HeLa cells was investigated, and it was observed that Sp1 protein expression predominated in G1 phase of the cell cycle (unpublished data). To con®rm these results Sp1 expression was analysed by immunostaining in synchronized and exponentially growing HBL-100 cells. Figure 1c shows that in exponentially growing HBL-100 cells Sp1 expression prevails in a subset of cells (Figure 1c, cycling) . In synchronized cells, low amounts of Sp1 were detected in the nuclei of S-and G2 phase cells ( Figure 1c , S and G2), whereas in the nuclei of G1 phase cells substantial amounts of Sp1 were seen (Figure 1c , G1).
Next we wished to determine how cell cycle dependent Sp1 expression is brought about. It has been shown by in vitro experiments that 54 amino acids of the N-terminus are required to target Sp1 to the proteasome-dependent system (Su et al., 1999) . Moreover, it was shown that ubiquitination of Sp1 is not required for degradation by the proteasome-dependent system (Su et al., 1999) . Proteasome-dependent degradation of Sp1 occurs under conditions of nutrient starvation and reduced O-glycosylation (Han and Kudlow, 1997) . To test whether Sp1 is degraded by the proteasome-dependent system during the cell cycle, we treated exponentially growing HBL-100 cells with the proteasome inhibitors N-acetyl-L-leucinyl-L-norleucinal (LLnL) and lactacystin, and analysed Sp1 by immunocytochemistry. In cycling HBL-100 cells Sp1 expression prevails in G1 phase (see Figure 1c) . However, after treatment with either lactacystin or LLnL virtually all HBL-100 cells expressed Sp1 in the nuclei ( Figure 2a , left and right panels). Next, we wished to con®rm these results by a biochemical approach. We isolated nuclei from HBL-100 cells which were treated for 1, 3, and 6 h with the proteasome inhibitor lactacystin, prepared nuclear extracts and used these for immunoblotting. Figure  2b shows that lactacystin treatment caused a signi®cant increase of Sp1 protein levels (lanes 4 ± 6) in comparison to untreated cells (lanes 1 ± 3). Similar results were obtained with proteasome inhibitor LLnL (not shown). Our data demonstrate that the transcription factor Sp1 is degraded by the proteasome-dependent system in a cell cycle dependent fashion.
Sp1 is required for cell cycle progression through G1 phase
To gain further insight into the function of Sp1 in the cell cycle, we used a dominant-negative mutant (deltaSp1) to inhibit cellular (endogeneous) Sp1 activity (Petersohn and Thiel, 1996) . The delta-Sp1 mutant contains amino acids 592 ± 758 of human Sp1. This fragment consists of the DNA binding domain of Sp1 which confers sequence-speci®c DNA interactions (Kadonaga et al., 1988) Delta-Sp1 lacks the glutamine-rich transactivation domain , and transient reporter gene assays demonstrated that this Sp1 mutant has no transactivating function. Moreover, it was shown that delta-Sp1 selectively inhibits Sp1-dependent reporter gene expression (Petersohn and Thiel, 1996) . We wished to express the deltaSp1 mutant in HeLa cells under control of a tetracyclin inducible expression system (Gossen and Bujard, 1992) and therefore created stable delta-Sp1 transfectant 4) ; 72 h (lanes 2 and 5) and 96 h (lanes 3 and 6) after treatment with doxocyclin. Expression of Delta-Sp1 was detected by Western blotting of the nuclear extracts using an antibody to the GST tag. Delta-Sp1 is indicated by an arrow. (b) Analysis of Sp1 expression in HeLa-Delta-Sp1 transfectant and HeLa mock transfectant cells. The same extracts as in (a) were used. Sp1 expression was detected by Western blotting using an antibody directed against Sp1. (c) Delta-Sp1 blocks transcription activity of cellular Sp1. Delta-Sp1 transfectant cells (Delta-Sp1) and mock control cells (Control) were analysed for endogenous Sp1 activity by CAT assay using a reporter plasmid containing four Sp1 binding sites upstream of a minimal promoter (Petersohn and Thiel, 1996) . The values obtained were normalized to beta-galactosidase control. (d) Delta-Sp1 transfectant cells exhibit cell cycle arrest in G1 phase. Delta-Sp1 transfectant cells and mock transfectant cells were grown as described in (a). Cells were harvested 48 h, 72 h and 96 h after doxocyclin treatment, and the cell cycle distribution was examined by FACS analysis. 2n and 4n populations are indicated G1 phase control by Sp1 E Grinstein et al
HeLa cell lines (HeLa-delta-Sp1) and mock transfectant cell lines (HeLa-mock), which just contain the empty vector. Expression of delta-Sp1 protein in the transfectant cells was veri®ed by immunoblotting with an antibody directed at the GST-tag of the Sp1 mutant ( Figure 3a) . It is shown that treatment with doxocyclin led to sustained delta-Sp1 protein expression ( Figure  3a , lanes 1 ± 3). The same extracts were analysed for wild-type Sp1 protein expression by Western blotting (Figure 3b ). The Figure shows that the transdominantnegative delta-Sp1 mutant does not signi®cantly aect endogeneous Sp1 protein expression. To test whether the transdominant-negative Sp1 mutant inhibits the function of endogeneous Sp1, we used an Sp1 responsive p-chloramphenicol acetyl transferase reporter gene (CAT). This reporter construct contains four Sp1 binding sites upstream of a minimal promoter (Petersohn and Thiel, 1996) . We transiently transfected HeLa-delta-Sp1 and HeLa-mock cells with the reporter construct and treated the cells with doxocyclin. The results are shown in Figure 3c . The CAT reporter gene was eciently expressed in transiently transfected HeLa-mock cells (Figure 3c, control) , indicating endogeneous Sp1 activity. In contrast, the delta-Sp1 mutant eciently inhibited endogeneous Sp1 as demonstrated by strongly reduced reporter gene expression in HeLa-delta-Sp1 cells which amounted to only 8% of the control (Figure 3c , delta-Sp1). Next, we investigated whether inhibition of Sp1 aects cell cycle progression in G1 phase. We determined the doubling times after delta-Sp1-HeLa induction and compared these with HeLa-mock cell lines. An inhibition of cell proliferation by delta-Sp1 was observed (unpublished results). We then analysed cell cycle distributions of doxocyclin treated HeLadelta-Sp1 cells by FACS analysis using doxocyclin treated HeLa-mock cells as control. Whereas the HeLa-mock cells showed a cell cycle distribution characteristic of exponentially growing cells, the cell cycle pro®le of HeLa-delta-Sp1 cells was altered. Figure 3d shows that an initially asynchronous population of HeLa-delta-Sp1 cells became a predominantly G1 population within 72 to 96 h after doxocyclin treatment. Thus Sp1 is required for cycle progression in G1 phase.
Inhibition of cyclin D1 and EGFR expression by delta Sp1 and induction of p27Kip1
Next, we wished to ®nd out how Sp1 facilitates cell cycle progression. In order to address this question, we investigated whether delta-Sp1 aects expression of certain cell cycle genes which function in G1 phase and the G1/S boundary. We examined the EGF receptor, cyclin D1, p27Kip1, Cdk2 and cyclin E. Figure 4 shows the results. It is evident that expression levels of the EGF receptor and cyclin D1 were strongly reduced in doxocyclin treated HeLa-delta-Sp1 cells. In contrast the levels of p27Kip1 were strongly increased. Cdk2 expression was inhibited to a lesser extent and cyclin E expression was almost not aected. Note that in the case of Cdk2 the delta-Sp1 mutant prevented formation of a faster moving form of Cdk2 which appears in S and G2 phase (Gu et al., 1992) . The levels of DP-1 and Ki67 proteins were not aected by the delta-Sp1 mutant (unpublished data). Protein amounts were controlled with a beta-actin antibody (Figure 4, bottom) .
Discussion
In this study we show that expression of Sp1 protein is cell cycle regulated with a predominance in G1 phase. Our results demonstrate that the proteasome-dependent system is involved in cell cycle dependent degradation of Sp1 before S phase. It has been shown that Sp1 can be degraded by the proteasome under Figure 4 Blocking of endogenous Sp1 activity modulates expression of G1 phase genes. Delta-Sp1 transfectant cells (lanes 1 and 2) and mock transfectant cells (lanes 3 and 4) were harvested 48 h and 72 h after treatment with doxocyclin, respectively. The expression of the EGF receptor, cyclin D1, p27Kip1, Cdk2 and Cyclin E was analysed by Western blotting. Western blot with an antibody to beta-actin served as internal control (bottom) conditions of nutrient starvation (Han and Kudlow, 1997; Su et al., 1999 Su et al., , 2000 , however, cell cycle dependent degradation of Sp1 is a novel ®nding. It is interesting to note that in the case of Sp1 ubiquitination is not needed for proteasome-dependent degradation (Han and Kudlow, 1997; Su et al., 1999) . The proteasome is involved in proteolysis of certain G1 and S phase regulators (reviewed in Yew, 2001 ). However, in many cases proteasome-dependent degradation is ubiquitination-dependent. For example, p27Kip1 protein is targeted for ubiquitination and degradation (Pagano et al., 1995) , and this occurs before the onset of S phase (reviewed in Tyers and Jorgensen, 2000) . The cascade of events which lead to the degradation of p27Kip1 is initiated by phosphorylation (Montagnoli et al., 1999) . It is conceivable that phosphorylation triggers targeting of Sp1 to the proteasome, and it has been shown that Sp1 is increasingly phosphorylated during G1 phase progression (Black et al., 1999) . Understanding how Sp1 is targeted for proper temporal degradation will be important areas for future study.
The ®nding that Sp1 expression predominates in G1 phase of the cell cycle prompted us to investigate the role of Sp1 for the cell cycle. We demonstrated with the help of a dominant-negative Sp1 mutant (deltaSp1) that cell cycle progression in G1 phase is dependent on Sp1 in epithelial cells. Furthermore, we demonstrated that Sp1 is required for ecient cyclin D1 and EGFR expression, both of which are required for cell cycle progression in G1 (Baldin et al., 1993; Quelle et al., 1993; Daub et al., 1996; Lipson et al., 1998; Ben-Bassat et al., 1999) . Thus our ®ndings explain, at least in part, how Sp1 dependent control of cell cycle progression in G1 is brought about.
It has been reported that Cyclin D1 gene transcription is cell cycle regulated and peaks in the G1 phase (Motokura et al., 1992) . The cyclin D1 gene promoter contains multiple Sp1 binding sites (Motokura and Arnold, 1993) , and Sp1-mediated activation of the cyclin D1 gene promoter by certain signal transduction pathways has been reported (Yan and Zi, 1997; Nagata et al., 2001) . Mutational analysis of the cyclin D1 promoter in combination with transient reporter gene assays showed that three of the four Sp1 binding sites are important for regulated expression of the cyclin D1 gene (Nagata et al., 2001) . Moreover it was demonstrated that the transactivation domain of Sp1 is involved in transcriptional activation of the cyclin D1 gene (Yan and Zi, 1997) . Thus, the involvement of Sp1 in transcriptional control of the cyclin D1 gene is well established. Our results reveal how Sp1 contributes to cell cycle stage speci®c expression of cyclin D1. In addition, we have shown here that delta-Sp1 strongly inhibited EGFR protein expression. This result suggests that endogeneous EGFR gene expression is also regulated by Sp1. Our ®ndings are in line with published data which initially showed by transient transfection assays in Drosophila SL2 cells that Sp1 regulates the EGFR gene promoter (Xu et al., 1993; Vallian et al., 1998) . We have found by using synchronized cells HeLa and HBL-100 that EGF receptor protein expression was restricted to the G1 phase of the cell cycle (unpublished results). Thus it is evident that Sp1 is also involved in regulating cell cycle dependent expression of the EGFR gene. Future experiments using microarrays will determine the full spectrum of G1 phase genes whose expression depends on Sp1.
The DNA recognition domains of Sp1 and Sp3 are highly related and for this reason Sp1 and Sp3 can bind to Sp1 sites (reviewed in Suske, 1999) . It is possible that delta-Sp1 inhibits both Sp1 and Sp3 thus complicating the interpretation of our results. However, in many cases Sp3 antagonizes the activity of Sp1 (Hagen et al., 1994; Birnbaum et al., 1995; Kumar and Butler, 1999) . Moreover, promoters which consist of several Sp1 sites are selectively repressed by Sp3 (Hagen et al., 1994; Birnbaum et al., 1995) . In this context it is important to note that the cyclin D1 and the EGFR promoters contain multiple Sp1 binding sites (Motokura and Arnold, 1993; Johnson et al., 1988) . Future work will determine the role of Sp3 for the cell cycle.
Expression of the delta-Sp1 mutant caused an induction of p27Kip1 expression. One could assume that Sp1 acts as a repressor of p27Kip gene expression. On the other hand, it is possible that a delta-Sp1 induced G1 arrest prevented p27Kip1 degradation by the proteasome-dependent system (Pagano et al., 1995) . The EGFR signal transduction pathway facilitates degradation of p27Kip protein, and inhibition of EGF receptor signaling up-regulates p27Kip1 expression leading to a cell cycle arrest in G1 (Wu et al., 1996; Busse et al., 2000; Lenferink et al., 2000) . It is thus likely that upregulation of p27Kip1 expression by delta-Sp1 is, at least in part, responsible for the observed G1 arrest in doxocyclin treated delta-Sp1 cells. Cdk2 protein is phosphorylated on threonine 160 in S phase cells and can be detected as a faster moving band in immunoblots (Gu et al., 1992) . In delta-Sp1 expressing cells this band was not detected (Figure 4 , blot Cdk2, lanes 1 and 2). We consider it likely that the G1 arrest induced by delta-Sp1 is responsible for this phenomenon.
Growth factors induce proliferation during the G1 phase of the cell cycle. At a point late in G1, termed the restriction point (Pardee, 1989) , cells lose their growth factor dependence and are committed to complete the mitotic cycle even in the absence of growth factors. Based on our results it is tempting to speculate that Sp1 has a role in controlling the restriction point thus balancing proliferation and cell dierentiation processes.
Materials and methods
Cell culture and synchronization
HBL-100 cells were maintained in RPMI 1640 medium, supplemented with 10% fetal calf serum and 2 mM L-G1 phase control by Sp1 E Grinstein et al glutamine; HeLa cells were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal calf serum. Where indicated, cells were treated with 20 mM lactacystin or 100 mM N-acetyl-L-leucinyl-L-norleucinal, as described (Pagano et al., 1995) . Detailed cell synchronization conditions and the controls have been described previously (Grinstein et al., 1996) . In brief, G1 phase cell populations were prepared by 20 mM lovastatin treatment for 24 h; S phase cells by 3 mM aphidicolin treatment for 24 h followed by a 2 h release in fresh medium; G2 phase cells by 3 mM aphidicolin treatment for 24 h followed by a 6 h release in fresh medium.
Preparation of cell extracts, Western blotting, EMSA and immunohistochemistry
Cell extracts were prepared as described previously (Grinstein et al., 1996) . Western blots were performed according to standard procedures. Rabbit polyclonal antibody directed against Sp1 (Santa Cruz, PEP2) was used in a 1 : 3000 dilution, mouse monoclonal antibody against cyclin D1 (Pharmingene) was used in a 1 : 1000 dilution, rabbit polyclonal antibody against EGF receptor (Santa Cruz) was used in a 1 : 3000 dilution, rabbit polyclonal antibody against Cyclin E (Santa Cruz) at a 1 : 3000 dilution, mouse monoclonal antibody to p27Kip1 (Novocastra Laboratories, UK) at a 1 : 1000 dilution, mouse monoclonal antibody to beta-actin (Sigma) at a 1 : 3000 dilution, rabbit polyclonal antibody to Oct-1 (Santa Cruz) at a 1 : 1000 dilution, rabbit polyclonal antibody against Glutathione S-transferase (GST) (Santa Cruz) was used in a 1 : 3000 dilution. For Western blotting, prestained molecular weight marker proteins (BioRad) were used. Molecular weights of the prestained proteins are indicated in the ®gures. Molecular weights of individual prestained proteins were taken from the instruction lea¯et supplied by BioRad. Immunoperoxidase staining was performed using vectra stain ABC kit (Vector laboratories), according to the manufacturer's protocol with antibody directed against Sp1 (Santa Cruz, PEP2). Electrophoretic mobility shift assays were performed as described (Grinstein et al., 1996) , with minor modi®cations. For the detection of Sp1 DNA binding Sp1 consensus sequence was used (Santa Cruz). In all EMS-assays, 5 mg nuclear extract were used with end-labeled Sp1 double-stranded oligonucleotide and 2.5 mg poly(dI-dC)(dI-dC). The EMSA-DNA binding buer contained 20 mM Tris (pH 8.0), 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 10% Glycerol and protease inhibitors. For immunoshifts Sp1 or DP1 antibodies (Santa Cruz) were added to the binding reaction and incubated for 20 min together with the labeled Sp1 oligonucleotide. The amounts of added antibodies are indicated in the ®gure.
Creation of stable transfectant cell clones
The pEBG-Sp1 plasmid, encoding a fusion protein consisting of GST, a nuclear localization sequence and the amino acids 592 ± 758 of human Sp1, corresponding to DNA-binding domain of human Sp1 (Petersohn and Thiel, 1996) was used to clone the insert (termed delta-Sp1) into the vector pUHD 10-3 (Gossen and Bujard, 1992) . The resulting construct was used to obtain stable HeLa-Delta-Sp1 transfectant cell lines, according to previously described procedure (Gossen and Bujard, 1992) . The pUHD 10-3 plasmid with no insert was used to obtain stable HeLa-mock transfectant cell lines. Induction of delta-Sp1 expression was attained by adding doxocyclin (10 mg/ml) to the cell cultures (Gossen and Bujard, 1992) .
Chloramphenicol acetyl transferase (CAT) assays
CAT assays were performed using a CAT reporter plasmid pSBII(GC)4CAT containing four Sp1 binding sites upstream of a minimal promoter (Petersohn and Thiel, 1996) . Transfection procedure was carried out by the calcium phosphate coprecipitation technique; 48 h after transfection, the cells were harvested and the CAT activity was determined using the CAT enzyme assay system (Promega) according to the manufacturer's speci®cations. The beta-galactosidase activity was measured and used to correct for variations in transfection eciencies.
Determination of cellular DNA content by FACS analysis
FACS analysis was performed as described (Grinstein et al., 1996) . In brief, 5610 5 cells were treated with ethanol for 1 h at 7208C, washed with phosphate-buered saline, incubated in 500 ml phosphate-buered saline containing 40 U/ml of RNAse A and 100 mg/ml propidium iodide for 30 min at 378C, and analysed by the¯uorescent-activated cell sorter using the Cellquest program (Beckton Dickinson).
